Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2016 Feb 29;25(5):807–814. doi: 10.1158/1055-9965.EPI-15-1044

Table 2.

Discounted costs, discounted quality-adjusted life expectancy, and incremental cost-effectiveness ratio for the base-case analysis (assuming biopsy-directed treatment adherence of 50%)

Strategy Cost Incremental cost Effectiveness (QALYs) Incremental effectiveness (QALYs) ICER ($/QALY)
Usual care $1,276 -- 17.943 -- --
See-and-treat $1,692 $417 17.949 0.006 $70,774

QALY: quality-adjusted life-year, ICER: incremental cost-effectiveness ratio.